Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet in dialysis patients with secondary hyperparathyroidism
2013-004958-18Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) (2 arms), sponsored by Amgen. Primary endpoint: Proportion of patients with at least 30% reduction in mean plasma intact parathyroid hormone. Started May 2014; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2013-004958-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004958-18.